MEDGINTRAS, UAB - financials and debts

Company age: 25 y. 8 mo.

Update

MEDGINTRAS - Company finances

EUR
2018
From: 2018-01-01
To: 2018-12-31
2019
From: 2019-01-01
To: 2019-12-31
2020
From: 2020-01-01
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 1,996,464 2,561,919 2,945,313 3,727,510 5,876,192 7,835,670 9,166,184 9,151,878
Profit before tax 181,046 159,224 465,217 183,702 340,005 1,470,020 1,573,546 633,581
Net profit 173,409 151,600 449,044 143,006 315,642 1,386,410 1,501,898 525,914
Equity 204,946 193,637 634,870 474,543 647,179 1,417,947 2,919,845 3,445,758
Liabilities 193,578 460,666 0 750,723 719,823 672,111 893,400 1,309,015
Non-current assets 104,722 215,421 335,629 422,623 356,715 319,444 949,833 2,300,718
Current assets 306,044 489,711 635,002 875,227 1,066,657 1,815,520 2,893,631 2,495,593
Total assets 410,766 705,132 970,631 1,297,850 1,423,372 2,134,964 3,843,464 4,796,311
Taxes paid
STI taxes - - - - - 1,157,948 1,216,623 1,275,925
Social insurance contributions - - - - - 1,041,401 1,195,438 1,343,036
Financial indicators
Revenue change y/y +19.4% +28.3% +15.0% +26.6% +57.6% +33.3% +17.0% -0.2%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 42.2% 21.5% 46.3% 11.0% 22.2% 64.9% 39.1% 11.0%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 84.6% 78.3% 70.7% 30.1% 48.8% 97.8% 51.4% 15.3%
Profit margin Net profit margin. Shows the overall profitability of the company. 8.7% 5.9% 15.2% 3.8% 5.4% 17.7% 16.4% 5.7%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. 9.1% 6.2% 15.8% 4.9% 5.8% 18.8% 17.2% 6.9%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 0.9 2.4 - 1.6 1.1 0.5 0.3 0.4
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. 20,547 25,015 26,084 27,731 28,758 34,877 40,159 37,649

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

MEDGINTRAS - Social security debts

From To Debt, €
2025-11-18 2025-11-24 115051.69
2025-10-16 2025-10-22 114759.53
2024-11-18 2024-12-15 0.01
2024-10-29 2024-11-13 0.01
2024-10-24 2024-10-27 0.01
2022-11-17 2022-11-18 304.51
2021-10-26 2021-11-02 28.39

MEDGINTRAS - VMI tax arrears

From To Overdue, €
2025-06-17 2025-06-18 37.64
2025-06-14 2025-06-16 844.52
2025-05-08 2025-05-08 11.6
2025-05-05 2025-05-07 10.9
2025-05-03 2025-05-04 15.4
2025-05-01 2025-05-02 1308.9
2025-04-04 2025-04-14 38.25
2025-04-02 2025-04-03 36.58
2025-02-20 2025-02-20 65.76
2024-12-12 2024-12-12 1013.6

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
MEDGINTRAS, UAB (company code 160289489) is a Private Limited Liability Company engaged in Medical specialists activities. In the latest financial year, 2025, the company generated revenue of €9.15M and net profit of €525.9K, with a profit margin of 5.7%. Revenue was broadly unchanged from 2024, when it reached €9.17M, while profit was lower than in 2024, when net profit stood at €1.50M. Compared with 2023, however, revenue increased from €7.84M, showing two-year growth of 16.8%. Over the same period, profitability eased from €1.39M in 2023 and €1.50M in 2024 to the 2025 level. At the end of 2025, total assets were €4.80M, equity €3.45M and liabilities €1.31M. The balance sheet remained strongly equity-backed, with an equity ratio of 71.8% and debt-to-equity of 0.38. Asset turnover was 1.91x. Revenue per employee was €37.7K and profit per employee €2.2K.